Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Insmed Inc (INSM)

Insmed Inc (INSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insmed Inc Shares Up 89.9% Since SmarTrend's Buy Recommendation (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on March 25th, 2020 at $17.88. In approximately 6 months, Insmed Inc has returned 89.93% as of today's recent price of $33.95.

INSM : 33.61 (+0.45%)
Insmed to Host R&D Day on September 30, 2020

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host...

INSM : 33.61 (+0.45%)
Insmed Inc Has Returned 66.8% Since SmarTrend Recommendation (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on March 25th, 2020 at $17.88. In approximately 6 months, Insmed Inc has returned 66.77% as of today's recent price of $29.81.

INSM : 33.61 (+0.45%)
Insmed to Present at Three September Conferences

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management...

INSM : 33.61 (+0.45%)
New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results...

INSM : 33.61 (+0.45%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of...

INSM : 33.61 (+0.45%)
Insmed Inc Shares Up 57.9% Since SmarTrend's Buy Recommendation (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on March 25th, 2020 at $17.88. In approximately 5 months, Insmed Inc has returned 57.87% as of today's recent price of $28.22.

INSM : 33.61 (+0.45%)
Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and Andrew Drechsler, have been appointed to the Company's...

INSM : 33.61 (+0.45%)
BXRX : 3.01 (-1.31%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, Aug. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the...

INSM : 33.61 (+0.45%)
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

INSM : 33.61 (+0.45%)
Insmed: 2Q Earnings Snapshot

BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $61.9 million in its second quarter.

INSM : 33.61 (+0.45%)
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results...

INSM : 33.61 (+0.45%)
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results...

INSM : 33.61 (+0.45%)
Insmed Inc Rises 1.36% on Heavy Volume: Watch For Potential Pullback

Insmed Inc (NASDAQ:INSM) traded in a range yesterday that spanned from a low of $29.44 to a high of $30.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.57...

INSM : 33.61 (+0.45%)
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Food...

INSM : 33.61 (+0.45%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of...

INSM : 33.61 (+0.45%)
Insmed Inc Shares Up 39.8% Since SmarTrend's Buy Recommendation (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on March 25th, 2020 at $17.88. In approximately 2 months, Insmed Inc has returned 39.80% as of today's recent price of $24.99.

INSM : 33.61 (+0.45%)
Insmed to Present at Two June Conferences

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that , Chairman...

INSM : 33.61 (+0.45%)
Insmed Inc Shares Up 38.6% Since SmarTrend's Buy Recommendation (INSM)

SmarTrend identified an Uptrend for Insmed Inc (NASDAQ:INSM) on March 25th, 2020 at $17.88. In approximately 2 months, Insmed Inc has returned 38.57% as of today's recent price of $24.77.

INSM : 33.61 (+0.45%)
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new data from...

INSM : 33.61 (+0.45%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar